Diabetes:

Indications for BAQSIMI:

Severe hypoglycemia.

Adults and Children:

<4yrs: not established. ≥4yrs: 3mg as single spray intranasally into one nostril. May repeat with new device after 15mins if no response. The dose does not require inhalation.

Contraindications:

Pheochromocytoma. Insulinoma.

Warnings/Precautions:

Increased blood pressure. Previously undiagnosed pheochromocytoma. Lack of efficacy in insulinoma; may cause hypoglycemia. Insufficient hepatic glycogen stores (eg, starvation, adrenal insufficiency, chronic hypoglycemia); treat with glucose. Pregnancy. Nursing mothers.

Pharmacologic Class:

Antihypoglycemic.

Interactions:

Transient increase in pulse and blood pressure may occur with beta-blockers. Loss of efficacy or may produce hypoglycemia with indomethacin. May potentiate the anticoagulant effect of warfarin.

Adverse Reactions:

Nausea, headache, vomiting, upper respiratory tract irritation (eg, rhinorrhea, nasal discomfort/congestion, cough, epistaxis), watery eyes, redness of eyes, itchy nose/throat/eyes; allergic reactions.

Generic Availability:

NO

How Supplied:

Pack—1, 2

Pricing for BAQSIMI

1 intranasal device of 3mg carton (Qty: 1)
Appx. price $287
GoodRx